Loading…
Loading…
PHRX does not currently pay a dividend.
See exactly how PHRX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PHRX and 80,000+ other tickers.
Pharmagen, Inc., a pharmaceutical company located in Silver Spring, Maryland, operates primarily as a distributor within the U.S. healthcare market. It provides a diverse range of specialty drugs to various medical clients, including hospitals, acute care centers, surgical facilities, and other healthcare practitioners nationwide. The company's offerings encompass sourcing and distributing specialty pharmaceuticals, blood plasma derivatives, unique medical products, vaccines, anti-infectives, and often hard-to-find medications. A key area of its expertise lies in plasma derivatives, which are…
Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting evaluation of Sairiyo's patented, orally bioavailable PD-001 formulation of cepharanthine for Hantavirus Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 51% owned by PharmaDrug and 49% owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate for Hantavirus ("HTNV").
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has closed the previously announced (see press release dated October 31, 2025) acquisition (the "Transaction") of limited partnership units of Canurta Limited Partnership ("Canurta"), the parent entity of Canurta Inc., a biotechnology company pioneering novel botanical therapeutics for inflammatory and neurodegenerative diseases. In connection with the completion of the first tranche, Akeem Gardner joined the Company's board of directors.
Toronto, Ontario--(Newsfile Corp. - October 31, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has agreed to issue $445,686 principal amount of secured convertible debentures to two current holders of the Company's secured convertible debentures that were past their maturity date. Each Debenture will mature on October 13, 2026 and will be convertible into common shares at a price of $0.05 (subject to adjustment).
Toronto, Ontario--(Newsfile Corp. - October 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has executed a definitive securities exchange agreement (the "Definitive Agreement") with Canurta Limited Partnership ("Canurta") and each of the limited partners of Canurta, the parent entity of Canurta Inc., a biotechnology company pioneering novel botanical therapeutics for inflammatory and neurodegenerative diseases. Dr. David Kideckel, Executive Chairman of PharmaDrug, commented: "Executing the Definitive Agreement with Canurta represents a major milestone in our strategy to expand PharmaDrug's biotechnology footprint through innovative botanical drug development.
Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), announces that the original news release captioned "PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc." published on July 30, 2025 referred, incorrectly, to the number of common shares of PharmaDrug to be issued in the second tranche of the proposed transaction and the total number of shares to be issued pursuant to both tranches. The press release incorrectly stated the number of shares to be issued in the second tranche as 32,827,438; the correct figure is 57,665,316.